The pharmacotherapeutic management of obstructive sleep apnea

References

• Berry RB, Brooks R, Gamaldo CE, et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications version 24. Darien, IL: American Academy of Sleep Medicine; 2017.
   Google Scholar
• Dempsey JA, Veasey SC, Morgan BJ, et al. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47–112.
   PubMed Web of Science ®Google Scholar
• Berry RB, Budhiraja R, Gottlieb DJ, et al. American academy of sleep M: rules for scoring respiratory events in sleep: update of the 2007. AASM manual for the scoring of sleep and associated events deliberations of the sleep apnea definitions task force of the american academy of sleep medicine. J Clin Sleep Med. 2012;8:597–619.
   PubMed Web of Science ®Google Scholar
• McNicholas WT, Bonsigore MR. Management committee of ECAB sleep apnea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29:156–178.
   PubMed Web of Science ®Google Scholar
• Hakim F, Gozal D, Kheirandish-Gozal L. Sympathetic and catecholaminergic alterations in sleep apnea with particular emphasis on children. Front Neurol. 2012;3:7.
   PubMedGoogle Scholar
• Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841–858.
   PubMed Web of Science ®Google Scholar
• Lacedonia D, Carpagnano GE, Patricelli G, et al. Prevalence of comorbidities in patients with obstructive sleep apnea syndrome, overlap syndrome and obesity hypoventilation syndrome. Clin Respir J. 2018;12(5):1905–1911.
   PubMed Web of Science ®Google Scholar
• Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003 Oct 8;290(14):1906–1914.
   PubMed Web of Science ®Google Scholar
• Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3:310–318.
   PubMed Web of Science ®Google Scholar
• Kushida CA, Littner MR, Hirshkowitz M, et al. American academy of sleep medicine: practice parameters for the use of continuous and bi-level positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006;29:375–380.
   PubMed Web of Science ®Google Scholar
• Barnes M, McEvoy RD, Banks S, et al. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. Am J Respir Crit Care Med. 2004;170:656–664.
   PubMed Web of Science ®Google Scholar
• Collard P, Pieters T, Aubert G, et al. Compliance with nasal CPAP in obstructive sleep apnea patients. Sleep Med Rev. 1997;1:33–44.
   PubMedGoogle Scholar
• Lanza A, Mariani S, Sommariva M, et al. Continuous positive airway pressure treatment with nasal pillows in obstructive sleep apnea: long-term effectiveness and adherence. Sleep Med. 2018;41:94–99.
   PubMed Web of Science ®Google Scholar
• Gulati A, Ali M, Davies M, et al. A prospective observational study to evaluate the effect of social and personality factors on continuous positive airway pressure (CPAP) compliance in obstructive sleep apnea syndrome. BMC Pulm Med. 2017 Mar 22;17(1):56.
   PubMedGoogle Scholar
• Simpson L, Hillman DR, Cooper MN, et al. High prevalence of undiagnosed obstructive sleep apnea in the general population and methods for screening for representative controls. Sleep Breath. 2013;17(3):967–973.
   PubMed Web of Science ®Google Scholar
• Bixler EO, Vgontzas AN, Lin HM, et al. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab. 2005;90(8):4510–4515.
   PubMed Web of Science ®Google Scholar
• Eckert DJ. Phenotypic approaches to obstructive sleep apnea – new pathways for targeted therapy. Sleep Med Rev. 2018;37:45–59.
   PubMed Web of Science ®Google Scholar
• Hooper RG. The relation between sleep and weight in a suburban sleep center: observations and speculations on apnea and weight. Nat Sci Sleep. 2016 Nov;21(8):315–320.
   Google Scholar
• Carberry JC, Amatoury J, Eckert DJ. Personalized management approach for OSA. Chest. 2018;153(3):744–755.
   PubMed Web of Science ®Google Scholar
• Osman AM, Carter SG, Carberry JC, et al. Obstructive sleep apnea: current perspectives. Nat Sci Sleep. 2018 Jan 23;10:21–34.
   PubMed Web of Science ®Google Scholar
• Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med. 2003;168(5):522–530.
   PubMed Web of Science ®Google Scholar
• Segal Y, Malhotra A, Pillar G. Upper airway length may be associated with the severity of obstructive sleep apnea syndrome. Sleep Breath. 2008;12(4):311–316.
   PubMed Web of Science ®Google Scholar
• Chi L, Comyn FL, Mitra N, et al. Identification of craniofacial risk factors for obstructive sleep apnea using three-dimensional MRI. Eur Respir J. 2011;38(2):348–358.
   PubMed Web of Science ®Google Scholar
• Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol (1985). 2005;99(4):1592–1599.
   PubMed Web of Science ®Google Scholar
• Saboisky JP, Butler JE, Fogel RB, et al. Tonic and phasic respiratory drives to human genioglossus motoneurons during breathing. J Neurophysiol. 2006;95(4):2213–2221.
   PubMed Web of Science ®Google Scholar
• Wilkinson V, Malhotra A, Nicholas CL, et al. Discharge patterns of human genioglossus motor units during sleep onset. Sleep. 2008;31(4):525–533.
   PubMed Web of Science ®Google Scholar
• Carberry JC, Jordan AS, White DP, et al. Upper airway collapsibility (Pcrit) and pharyngeal dilator muscle activity are sleep stage dependent. Sleep. 2016;39(3):511–521.
   PubMed Web of Science ®Google Scholar
• Younes M. Role of arousals in the pathogenesis of obstructive sleep apnea. Am J Respir Crit Care Med. 2004;169(5):623–633.
   PubMed Web of Science ®Google Scholar
• Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230–1235.
   PubMed Web of Science ®Google Scholar
• Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217–1239.
   PubMed Web of Science ®Google Scholar
• Wang F, Xiong X, Xu H, et al. The association between obstructive sleep apnea syndrome and metabolic syndrome: a confirmatory factor analysis. Sleep Breathing. 2019. DOI:10.1007/s11325-019-01804-8.
   Web of Science ®Google Scholar
• Yee BJ, Phillips CL, Banerjee D, et al. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnea. Int J Obes (Lond). 2007;31(1):161–168.
   PubMed Web of Science ®Google Scholar
• Ferland A, Poirier P, Series F. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnea patients. Eur Respir J. 2009;34(3):694–701.
   PubMed Web of Science ®Google Scholar
• Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019 Apr;27(4):591–602.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30:1480–1486.
   PubMed Web of Science ®Google Scholar
• Winslow DH, Bowden CH, DiDonato KP, et al. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529–1539.
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes Metab. 2009;11(Suppl 3):26–34.
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 30 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes. 2016;40(8):1310–1319.
   PubMed Web of Science ®Google Scholar
• Drager LF, Brunoni AR, Jenner R, et al. Effects of CPAP on body weight in patients with obstructive sleep apnea: a meta-analysis of randomized trials. Thorax. 2015;70(3):258–264.
   PubMed Web of Science ®Google Scholar
• An Y, Li Y, Kang D, et al. The effects of nasal decongestion on obstructive sleep apnea. Am J Otolaryngol. 2019 Jan–Feb;40(1):52–56.
   PubMed Web of Science ®Google Scholar
• Series F, Cormier Y. Effects of protriptyline on diurnal and nocturnal oxygenation in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1990;113(7):507–511.
   PubMed Web of Science ®Google Scholar
• Series F, Marc I, Cormier Y, et al. Long-term effects of protriptyline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;147(6 Pt 1):1487–1490.
   PubMedGoogle Scholar
• Taranto-Montemurro L, Edwards BA, Sands SA, et al. Desipramine increases genioglossus activity and reduces upper airway collapsibility during non-REM sleep in healthy subjects. Am J Respir Crit Care Med. 2016;194(7):878–885.
   PubMed Web of Science ®Google Scholar
• Taranto-Montemurro L, Sands SA, Edwards BA, et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J. 2016;48(5):1340–1350.
   PubMed Web of Science ®Google Scholar
• Osanai S, Akiba Y, Fujiuchi S, et al. Depression of peripheral chemosensitivity by a dopaminergic mechanism in patients with obstructive sleep apnea syndrome. Eur Respir J. 1999;13(2):418–423.
   PubMed Web of Science ®Google Scholar
• Larrain A, Kapur VK, Gooley TA, et al. Pharmacological treatment of obstructive sleep apnea with a combination of pseudoephedrine and domperidone. J Clin Sleep Med. 2010;6(2):117–123.
   PubMed Web of Science ®Google Scholar
• Grace KP, Hughes SW, Horner RL. Identification of a pharmacological target for genioglossus reactivation throughout sleep. Sleep. 2014;37(1):41–50.
   PubMed Web of Science ®Google Scholar
• Taranto-Montemurro L, Sands SA, Azarbarzin A, et al. Effect of 4-aminopyridine on genioglossus muscle activity during sleep in healthy adults. Ann Am Thorac Soc. 2017;14(7):1177–1183.
   PubMed Web of Science ®Google Scholar
• Wirth KJ, Steinmeyer K, Ruetten H. Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs. Sleep. 2013;36(5):699–708.
   PubMed Web of Science ®Google Scholar
• Hedner J, Zou D. Drug therapy in obstructive sleep apnea. Sleep Med Clin. 2018;13:203–217.
   PubMed Web of Science ®Google Scholar
• Veasey SC, Chachkes J, Fenik P, et al. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep. 2001;24(2):155–160.
   PubMed Web of Science ®Google Scholar
• Stradling J, Smith D, Radulovacki M, et al. Effect of ondansetron on moderate obstructive sleep apnea, a single night, placebo-controlled trial. J Sleep Res. 2003;12(2):169–170.
   PubMed Web of Science ®Google Scholar
• Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest. 1991;100(2):416–421.
   PubMed Web of Science ®Google Scholar
• Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep. 1999;22(1):61–67.
   PubMed Web of Science ®Google Scholar
• Berry RB, Yamaura EM, Gill K, et al. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep. 1999;22(8):1087–1092.
   PubMed Web of Science ®Google Scholar
• Carley DW, Olopade C, Ruigt GS, et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep. 2007;30(1):35–41.
   PubMed Web of Science ®Google Scholar
• Marshall NS, Yee BJ, Desai AV, et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep. 2008;31(6):824–831.
   PubMed Web of Science ®Google Scholar
• Gothe B, Strohl KP, Levin S, et al. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest. 1985;87(1):11–17.
   PubMed Web of Science ®Google Scholar
• Zevin S, Swed E, Cahan C. Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome. Am J Ther. 2003;10(3):170–175.
   PubMedGoogle Scholar
• Hedner J, Kraiczi H, Peker Y, et al. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med. 2003;168(10):1246–1251.
   PubMed Web of Science ®Google Scholar
• Sukys-Claudino L, Moraes W, Guilleminault C, et al. Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial. Sleep Med. 2012;13(3):290–296.
   PubMed Web of Science ®Google Scholar
• Li Y, Owens RL, Sands S, et al. The effect of donepezil on arousal threshold and apnea-hypopnea index. A randomized, double-blind, cross-over study. Ann Am Thorac Soc. 2016;13(11):2012–2018.
   PubMed Web of Science ®Google Scholar
• Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest. 1992;101(3):753–757.
   PubMed Web of Science ®Google Scholar
• Orth MM, Grootoonk S, Duchna HW, et al. Short-term effects of oral theophylline in addition to CPAP in mild to moderate OSA. Respir Med. 2005;99(4):471–476.
   PubMed Web of Science ®Google Scholar
• Uauy R, Shapiro DL, Smith B, et al. Treatment of severe apnea in prematures with orally administered theophylline. Pediatrics. 1975;55:595–598.
   PubMed Web of Science ®Google Scholar
• Carberry JC, Fisher LP, Grunstein RR, et al. Role of common hypnotics on the phenotypic causes of OSA: paradoxical effects of zolpidem. Eur Respir J. 2017;50(6):pii:1701344.
   PubMed Web of Science ®Google Scholar
• Fleury Curado T, Fishbein K, Pho H, et al. Chemogenetic stimulation of the hypoglossal neurons improves upper airway patency. Sci Rep. 2017;7:44392.
   PubMed Web of Science ®Google Scholar
• Horton GA, Fraigne JJ, Torontali ZA, et al. Activation of the hypoglossal to tongue musculature motor pathway by remote control. Sci Rep. 2017;7:45860.
   PubMed Web of Science ®Google Scholar
• Taranto-Montemurro L, Messineo L, Sands SA, et al. The combination of atomaxetine and oxybutynin greatly reduces obstructive sleep apnea severity. a randomized, placebo-controlled, doublle-blind crossover trial. Am J Respir Crit Care Med. 2019 May 15;199(10):1267–1276.
   PubMed Web of Science ®Google Scholar
• Burdyga G, Lal S, Varro A, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci. 2004;24(11):2708–2715.
   PubMed Web of Science ®Google Scholar
• Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep. 2018 Jan 1;41(1):1–13.
   PubMed Web of Science ®Google Scholar
• Eckert DJ, Owens RL, Kehlmann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnea/hypopnea index in obstructive sleep apnea patients with a low drug therapy in obstructive sleep apnea arousal threshold. Clin Sci (Lond). 2011;120(12):505–514.
   PubMed Web of Science ®Google Scholar
• Smales ET, Edwards BA, Deyoung PN, et al. Trazodone effects on obstructive sleep apnea and non-REM arousal threshold. Ann Am Thorac Soc. 2015;12(5):758–764.
   PubMed Web of Science ®Google Scholar
• Liu HM, Chiang IJ, Kuo KN, et al. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. Ther Adv Respir Dis. 2016;11(1):20–29.
   PubMed Web of Science ®Google Scholar
• Edwards BA, Sands SA, Eckert DJ, et al. Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnea. J Physiol. 2012;590(5):1199–1211.
   PubMed Web of Science ®Google Scholar
• Nussbaumer-Ochsner Y, Latshang TD, Ulrich S, et al. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest. 2012;141(1):131–138.
   PubMed Web of Science ®Google Scholar
• Eskandari D, Zou D, Karimi M, et al. Zonisamide reduces obstructive sleep apnea: a randomized placebo-controlled study. Eur Respir J. 2014;44(1):140–149.
   PubMed Web of Science ®Google Scholar
• Duran J, Esnaola S, Rubio R, et al. Obstructive sleep apnea-hypopnea and related clinical features in a population based sample of subjects aged 30–70 yr. Am J Respir Crit Care Med. 2001;163(3 Pt 1):685–689.
   PubMed Web of Science ®Google Scholar
• Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab. 2006;8(3):250–260.
   PubMed Web of Science ®Google Scholar
• Hedner J, Grote L, Bonsignore M, et al. The European Sleep Apnea Database (ESADA): report from 22 European sleep laboratories. Eur Respir J. 2011;38(3):635–642.
   PubMed Web of Science ®Google Scholar
• Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271–2277.
   PubMed Web of Science ®Google Scholar
• Sánchez-de-la-Torre M, Campos-Rodriguez F, Barbé F. Obstructive sleep apnea and cardiovascular disease. Lancet Respir Med. 2013;1(1):61–72.
   PubMed Web of Science ®Google Scholar
• Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest. 2007;132:440–446.
   PubMed Web of Science ®Google Scholar
• Gaddam K, Pimienta E, Thomas J, et al. Spironolactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24:532–537.
   PubMed Web of Science ®Google Scholar
• Khurshid K, Yabes J, Weiss PM, et al. Effect on anti-hypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med. 2016;12(8):1143–1151.
   PubMed Web of Science ®Google Scholar
• Shepherd KL, James AL, Musk AW, et al. Gastro-esophageal reflux symptoms are related to the presence and severity of obstructive sleep apnea. J Sleep Res. 2011;20:241–249.
   PubMed Web of Science ®Google Scholar
• Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:1914–1922.
   PubMed Web of Science ®Google Scholar
• Launois SH, Tamisier R, Levy P, et al. On treatment but still sleepy: cause and management of residual sleepiness in obstructive sleep apnea. Curr Opin Pulm Med. 2013;19(6):601–608.
   PubMed Web of Science ®Google Scholar
• Pepin JL, Viot-Blanc V, Escourrou P, et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnea patients: the French multicentre study. Eur Respir J. 2009;33:1062–1067.
   PubMed Web of Science ®Google Scholar
• Gasa M, Tamisier R, Launois SH, et al. Residual sleepiness in sleep apnea& patients treated by continuous positive airway pressure. J Sleep Res. 2013;22:389–397.
   PubMed Web of Science ®Google Scholar
• Antic NA, Catcheside P, Buchan C, et al. The effect of CPAP in normalizing daytime sleepiness, quality of life, and neurocognitive function in patients with moderate to severe OSA. Sleep. 2011;34:111–119.
   PubMed Web of Science ®Google Scholar
• Johns MW. Sensitivity and specificity of the Multiple Sleep Latency Test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res. 2000;9:5–11.
   PubMed Web of Science ®Google Scholar
• Pepin J, Launois S, Tamisier R, et al. Sleepiness due to sleep-related breathing disorders. In: Thorpy MJ, Billiard M, editors. Sleepiness: causes, consequences and treatment. Cambridge, UK: Cambridge University Press; 2011. p. 154–167.
   Google Scholar
• MacLean AW, Davies DR, Thiele K. The hazards and prevention of driving while sleepy. Sleep Med Rev. 2003;7:507–521.
   PubMed Web of Science ®Google Scholar
• Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;28:464–471.
   PubMed Web of Science ®Google Scholar
• Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 Jun;3(3):349–364.
   PubMedGoogle Scholar
• Chapman JL, Vakulin A, Hedner J, et al. Modafinil/armodafinil in obstructive sleep apnea: a systematic review and meta-analysis. Eur Respir J. 2016;47(5):1420–1428.
   PubMed Web of Science ®Google Scholar
• Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001;164:1675–1681.
   PubMed Web of Science ®Google Scholar
• Avellar AB, Carvalho LB, Prado GF, et al. Pharmacotherapy for residual excessive sleepiness and cognition in CPAP-treated patients with obstructive sleep apnea syndrome: a systematic review and meta-analysis. Sleep Med Rev. 2016;30:97–107.
   PubMed Web of Science ®Google Scholar
• Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163:713–721.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomized trial. Lancet Neurol. 2013;12(11):1068–1075.
   PubMed Web of Science ®Google Scholar
• Herring WJ, Liu K, Hutzelmann J, et al. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. Sleep Med. 2013;14:955–996.
   PubMed Web of Science ®Google Scholar
• Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367–376.
   PubMed Web of Science ®Google Scholar
• Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2018 Dec. DOI:10.1164/rccm201806-1100OC.
   Web of Science ®Google Scholar
• Abad VC, Guilleminault C. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med. 2018 Nov;2:1–13.
   Google Scholar
• Strollo PJ, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019 Feb;155(2):364–374.
   PubMed Web of Science ®Google Scholar
• Taylor D. The opportunity: superior treatment of narcolepsy and cataplexy SKL- N05; [ cited 2018 May 20].
   Google Scholar
• Sands SA, Edwards BA, Terrill PI, et al. Phenotyping pharyngeal pathophysiology using polysomnography in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2018 May 1;197(9):1187–1197.
   PubMed Web of Science ®Google Scholar